WEBULL
News
EPRX
8.50
+1.80%
0.15
Cantor Fitzgerald Sticks to Its Buy Rating for Eupraxia Pharmaceuticals (EPRX)
TipRanks · 13h ago
Weekly Report: what happened at EPRX last week (0202-0206)?
Weekly Report · 17h ago
Eupraxia Pharmaceuticals management to meet with Cantor
TipRanks · 02/02 18:55
Weekly Report: what happened at EPRX last week (0126-0130)?
Weekly Report · 02/02 09:41
Weekly Report: what happened at EPRX last week (0119-0123)?
Weekly Report · 01/26 09:41
Weekly Report: what happened at EPRX last week (0112-0116)?
Weekly Report · 01/19 09:44
Cantor Fitzgerald Maintains Overweight on Eupraxia Pharmaceuticals, Raises Price Target to $19
Benzinga · 01/15 12:40
Eupraxia Pharmaceuticals price target raised to $19 from $11 at Cantor Fitzgerald
TipRanks · 01/15 12:35
Weekly Report: what happened at EPRX last week (0105-0109)?
Weekly Report · 01/12 09:43
H.C. Wainwright Keeps Their Buy Rating on Eupraxia Pharmaceuticals (EPRX)
TipRanks · 01/09 11:36
HC Wainwright & Co. Reiterates Buy on Eupraxia Pharmaceuticals, Maintains $12 Price Target
Benzinga · 01/09 11:14
Eupraxia Therapeutics: Positive EP-104GI EoE Data, Strong Safety Profile, and Solid Cash Runway Support Buy Rating
TipRanks · 01/08 19:55
Eupraxia Trial Data Shows Lasting Tissue Healing In Patients With Inflamed Esophagus
Benzinga · 01/08 18:10
Eupraxia Pharmaceuticals Announces Positive Tissue Health Data From Its Ongoing RESOLVE Trial
NASDAQ · 01/08 14:11
Eupraxia Posts Strong Mid-Stage Data for Once-Yearly EoE Therapy EP-104GI
TipRanks · 01/08 13:28
Eupraxia Pharma Reports 12-Week And 36-Week Tissue Health Data From Ongoing Phase 1b/2a Part Of RESOLVE Trial Evaluating EP-104GI For Treatment Of Eosinophilic Esophagitis
Benzinga · 01/08 12:43
Eupraxia reports positive data from Phase 1b/2a part of RESOLVE trial
TipRanks · 01/08 12:43
Eupraxia Pharmaceuticals Reports Positive 12- and 36-Week Data from EP-104GI EoE Trial
Reuters · 01/08 12:34
EUPRAXIA PHARMACEUTICALS INC - EP-104GI WELL TOLERATED WITH NO SERIOUS ADVERSE EVENTS
Reuters · 01/08 12:34
Eupraxia Pharmaceuticals Reports Positive Tissue Health Data from its Ongoing RESOLVE Trial in Eosinophilic Esophagitis Demonstrating Near-Complete Improvement on Biopsy
Barchart · 01/08 06:34
More
Webull provides a variety of real-time EPRX stock news. You can receive the latest news about Eupraxia Pharmac through multiple platforms. This information may help you make smarter investment decisions.
About EPRX
Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. The Company is focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. DiffuSphere, a proprietary, polymer-based micro-sphere technology, is designed to facilitate targeted drug delivery of both existing and novel drugs. The Company’s EP-104GI is in a Phase Ib/IIa trial, the RESOLVE trial, for the treatment of eosinophilic esophagitis (EoE). EP-104GI is administered as an injection into the esophageal wall, providing local delivery of drug. The Company also completed a Phase IIb clinical trial (SPRINGBOARD) of EP-104IAR for the treatment of pain due to knee osteoarthritis. In addition, the Company is developing a pipeline of later and earlier-stage long-acting formulations. Its potential pipeline indications include candidates for other inflammatory joint indications and oncology.